Solifenacin succinate for the treatment of overactive bladder

Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):345-50. doi: 10.1517/17425250902762866.

Abstract

Solifenacin succinate, a competitive muscarinic receptor antagonist, is one of the newer options for the treatment of overactive bladder in men and women.

Objective: To review the pharmacology, efficacy and tolerability for the treatment of overactive bladder with solifenacin succinate.

Methods: A literature search was done using the keywords YM905 and solifenacin succinate.

Conclusion: Solifenacin succinate was shown to be effective for symptom control with an increase in volume voided, improvement in quality of life and a decrease in a common side effect of dry mouth compared to other medications.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Female
  • Humans
  • Male
  • Muscarinic Antagonists / administration & dosage*
  • Muscarinic Antagonists / adverse effects
  • Muscarinic Antagonists / pharmacokinetics
  • Quality of Life
  • Quinuclidines / administration & dosage*
  • Quinuclidines / adverse effects
  • Quinuclidines / pharmacokinetics
  • Solifenacin Succinate
  • Tetrahydroisoquinolines / administration & dosage*
  • Tetrahydroisoquinolines / adverse effects
  • Tetrahydroisoquinolines / pharmacokinetics
  • Urinary Bladder, Overactive / drug therapy*

Substances

  • Muscarinic Antagonists
  • Quinuclidines
  • Tetrahydroisoquinolines
  • Solifenacin Succinate